Search alternatives:
significant level » significance level (Expand Search), significance levels (Expand Search), significant gender (Expand Search)
level decrease » levels decreased (Expand Search), level increased (Expand Search), level disease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
significant level » significance level (Expand Search), significance levels (Expand Search), significant gender (Expand Search)
level decrease » levels decreased (Expand Search), level increased (Expand Search), level disease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
-
1101
Variables obtained from the SF-36 quality of life questionnaire in each experimental group.
Published 2025Subjects: -
1102
-
1103
-
1104
-
1105
-
1106
-
1107
Distribution of background characteristics of the study participants (N = 18255).
Published 2025Subjects: -
1108
-
1109
-
1110
Unsupervised hierarchical clustering for benign samples only (nontreatment, STT, and LTT groups).
Published 2025Subjects: -
1111
-
1112
-
1113
Combined Morphological and IHC Data: Combined Morphological and Immunohistochemistry Data.
Published 2025Subjects: -
1114
-
1115
Morphologic changes after dihydrotestosterone (DHT) treatment.1A: Diffuse lobular atrophy (20x).
Published 2025Subjects: -
1116
-
1117
-
1118
-
1119
Restricted cubic spline plots showing the association between changes in PAL and risk of CVD.
Published 2025Subjects: -
1120
Logistic Regression Analysis of the Association between PALs (MET-minutes/week) and CVD.
Published 2025Subjects: